Menu Search
Equities

Sino Biopharmaceutical Ltd

1177:HKG.HZ

Sino Biopharmaceutical Ltd

Actions
  • Price (HKD)3.30
  • Today's Change-0.08 / -2.37%
  • Shares traded42.39m
  • 1 Year change-12.47%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sino Biopharmaceutical Limited is an investment holding company principally engaged in the medicine products business. The Company operates through three business segments. The Modernized Chinese Medicine and Chemical Medicine segment is engaged in the manufacture, sale and distribution of modernized Chinese medicine products and western medicine products. The Investment segment is principally engaged in the long term and short term investments. The Other segment is principally engaged in the related medical and hospital business.

  • Revenue in HKD (TTM)28.78bn
  • Net income in HKD2.15bn
  • Incorporated2000
  • Employees24.44k
  • Location
    Sino Biopharmaceutical LtdUnit 09, 41F, Office TowerConvention Plaza, No. 1 Harbour RoadWanchai Hong KongHKG
  • Phone+852 28029886
  • Fax+852 28800847
  • Websitehttp://www.sinobiopharm.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.